We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
Read MoreHide Full Article
Shares of uniQure (QURE - Free Report) were up 7.08% during market hours after the company announced that its partner CSL Behring received FDA approval for one-time gene therapy, Hemgenix (etranacogene dezaparvovec-drlb), for treating hemophilia B patients above 18 years.
uniQure conducted the research and clinical development for the product. CSL Behring is a subsidiary of CSL Limited.
Hemgenix is the first FDA-approved gene therapy for treating hemophilia B.
The biologics license application (BLA) for etranacogene dezaparvovec, was submitted in March 2022 by CSL, and accepted for priority review by the FDA in May 2022.
CSL Behring is uniQure’s global commercialization partner for etranacogene dezaparvovec and is solely responsible for the development, regulatory activities and commercialization associated with etranacogene dezaparvovec, since May 2021. uniQure is now responsible for the global manufacturing of the product.
Hemophilia B is a rare bleeding disorder caused by a missing factor IX, known as the clotting protein. Symptoms of the disease include profuse bleeding after an injury, surgery and sometimes even without a clear cause. These bleeding episodes can lead to serious complications for an individual.
Hemgenix has been approved for treating adults with hemophilia B who are currently being treated with factor IX prophylaxis therapy, have a current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes.
It is a one-time gene therapy product consisting of a viral vector-carrying gene for clotting factor IX, which helps increase blood levels of factor IX, thereby limiting bleeding episodes. The treatment is given as a single dose of IV infusion.
Hemgenix’s FDA approval is based on results from the pivotal HOPE-B study, which demonstrated that after administering the drug, patients produced mean factor IX activity of 39% at six months and 36.7% at 24 months. The mean adjusted annualized bleeding rate (ABR) for all bleeds was also reduced by 54% after seven to 18 months of administering Hemgenix compared with the six-month lead-in period on factor IX prophylactic replacement therapy. 94% of the subjects treated with Hemgenix discontinued using prophylaxis therapy.
No severe adverse events were reported from the study.
uniQure has rallied 29.7% in the year-to-date period against the industry’s decline of 17.8%.
Immunocore’s loss per share estimates for 2022 have narrowed from $1.25 to 97 cents over the past 30 days. The loss per share for 2023 has narrowed from $1.69 to $1.10 in the same time frame.
Earnings of Immunocore beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. The average earnings surprise for IMCR is 68.34%.
AVEO Pharmaceuticals loss per share estimates for 2022 have narrowed down from 94 cents to 68 cents over the past 30 days. The earnings estimate for 2023 have remained steady at improved from 41 cents to 52 cents in the same time frame.
Earnings of AVEO beat estimates in three of the trailing four quarters, while missing the same in the reaming occasion. The average earnings surprise for AVEO is 19.87%.
Eton Pharmaceuticals’ loss per share estimates for 2022 have remained steady at 44 cents in the past 30 days. The earnings per share for 2023 have remained steady at a cent in the same time frame.
Earnings of Eton missed estimates in three of the trailing four quarters, while beating the same on the remaining occasion. The average earnings surprise for ETON is 115.63%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
uniQure (QURE) Partner Gets FDA Nod for Hemophilia B Gene Therapy
Shares of uniQure (QURE - Free Report) were up 7.08% during market hours after the company announced that its partner CSL Behring received FDA approval for one-time gene therapy, Hemgenix (etranacogene dezaparvovec-drlb), for treating hemophilia B patients above 18 years.
uniQure conducted the research and clinical development for the product. CSL Behring is a subsidiary of CSL Limited.
Hemgenix is the first FDA-approved gene therapy for treating hemophilia B.
The biologics license application (BLA) for etranacogene dezaparvovec, was submitted in March 2022 by CSL, and accepted for priority review by the FDA in May 2022.
CSL Behring is uniQure’s global commercialization partner for etranacogene dezaparvovec and is solely responsible for the development, regulatory activities and commercialization associated with etranacogene dezaparvovec, since May 2021. uniQure is now responsible for the global manufacturing of the product.
Hemophilia B is a rare bleeding disorder caused by a missing factor IX, known as the clotting protein. Symptoms of the disease include profuse bleeding after an injury, surgery and sometimes even without a clear cause. These bleeding episodes can lead to serious complications for an individual.
Hemgenix has been approved for treating adults with hemophilia B who are currently being treated with factor IX prophylaxis therapy, have a current or historical life-threatening hemorrhage or have repeated, serious spontaneous bleeding episodes.
It is a one-time gene therapy product consisting of a viral vector-carrying gene for clotting factor IX, which helps increase blood levels of factor IX, thereby limiting bleeding episodes. The treatment is given as a single dose of IV infusion.
Hemgenix’s FDA approval is based on results from the pivotal HOPE-B study, which demonstrated that after administering the drug, patients produced mean factor IX activity of 39% at six months and 36.7% at 24 months. The mean adjusted annualized bleeding rate (ABR) for all bleeds was also reduced by 54% after seven to 18 months of administering Hemgenix compared with the six-month lead-in period on factor IX prophylactic replacement therapy. 94% of the subjects treated with Hemgenix discontinued using prophylaxis therapy.
No severe adverse events were reported from the study.
uniQure has rallied 29.7% in the year-to-date period against the industry’s decline of 17.8%.
Image Source: Zacks Investment Research
uniQure N.V. Price
uniQure N.V. price | uniQure N.V. Quote
Zacks Rank and Stocks to Consider
uniQure currently has a Zacks Rank #3 (Hold).
Some better-ranked stocks in the same sector include Immunocore (IMCR - Free Report) , AVEO Pharmaceuticals and Eton Pharmaceuticals (ETON - Free Report) , each carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Immunocore’s loss per share estimates for 2022 have narrowed from $1.25 to 97 cents over the past 30 days. The loss per share for 2023 has narrowed from $1.69 to $1.10 in the same time frame.
Earnings of Immunocore beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion. The average earnings surprise for IMCR is 68.34%.
AVEO Pharmaceuticals loss per share estimates for 2022 have narrowed down from 94 cents to 68 cents over the past 30 days. The earnings estimate for 2023 have remained steady at improved from 41 cents to 52 cents in the same time frame.
Earnings of AVEO beat estimates in three of the trailing four quarters, while missing the same in the reaming occasion. The average earnings surprise for AVEO is 19.87%.
Eton Pharmaceuticals’ loss per share estimates for 2022 have remained steady at 44 cents in the past 30 days. The earnings per share for 2023 have remained steady at a cent in the same time frame.
Earnings of Eton missed estimates in three of the trailing four quarters, while beating the same on the remaining occasion. The average earnings surprise for ETON is 115.63%.